Episode image

FCR vs. BR - Is One Better?


Episode   ·  0 Play

Episode  ·  4:23  ·  Aug 26, 2016


Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.

4m 23s  ·  Aug 26, 2016

© 2016 Spreaker (OG)